House Democrats contend the $15 per hour minimum wage bill will lift workers who have not seen the benefits of a strong economy.Politicsread more
The Philadelphia Fed saw its primary gauge measuring the sector jump from 0.3 in June to 21.8, far better than Wall Street estimates of 5 and the highest in a year.Economyread more
Stocks erased earlier losses, but the rise was kept in check as Wall Street digested a mixed batch of corporate earnings results.US Marketsread more
"It's better to take preventative measures than to wait for disaster to unfold," Williams told the annual meeting of the Central Bank Research Association.The Fedread more
The fact that interest rates are relatively low makes the idea of a so-called insurance rate cut later this month an attractive option for the Fed.Market Insiderread more
Video of the event does not show the president disagreeing with his supporters. Instead, it shows that Trump paused as the chant began, allowing his supporters to continue...Politicsread more
President Trump said he's looking at the JEDI Contract that will be awarded to Microsoft or Amazon.Technologyread more
Wealthy clients liquidate some investments every year to cover their tax bill, so presumably this was higher than what Morgan Stanley has seen previously.Financeread more
Hacker Square at Facebook's headquarters pays homage to the company's early motto of moving fast and breaking things.Technologyread more
It's tempting to view Netflix as a possible replacement for the entire media ecosystem. But execs on its Q2 earnings call showed lower ambitions: It just wants to create the...Technologyread more
These are the stocks posting the largest moves midday.Market Insiderread more
"Over the past year, we've seen far too many examples of drug companies raising prices excessively for long-standing, life-saving treatments with little or no new innovation or R&D," Clinton said in a statement.
The statement cited Mylan's EpiPen price increases as the latest example.
"This is not an isolated problem," the statement said. "Between 2008 and 2015, drug makers increased the prices of almost 400 generic drugs by over 1,000 percent. Many of these companies are an example of a troubling trend — manufacturers that do not even develop the drug themselves, but acquire it and raise the price."
The Clinton campaign said the plan would:
Earlier this month, Clinton first weighed into the EpiPen controversy in a tweet:
In a statement linked from the tweet, Clinton said Mylan should lower the costs, "immediately."
Following pressure from Clinton and Capitol Hill, Mylan took steps to lower the price of the life-saving allergy treament.
The drugmaker said Monday it plans to launch a generic EpiPen Auto Injector at a discount of more than 50 percent. The list price will be $300 for a two pack. Mylan expects to launch the generic in several weeks.
Last week, Mylan said it was reducing the cost of branded EpiPens to eligible consumers through the use of a savings card that will cover up to $300 for the EpiPen two pack.
Mylan CEO Heather Bresch struggled in a recent CNBC interview to justify the repeated big price hikes to a retail cost of more than $600.
Mylan basically has a monopoly on the delivery system, with Sanofi's Auvi-Q exiting the market last year due to a recall, and Teva's generic version failing to receive regulatory approval.
— Reuters contributed to this report.